SUSVIMO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUSVIMO (SUSVIMO).
Ranibizumab is a humanized monoclonal antibody fragment that binds to and inhibits the activity of vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability.
| Metabolism | Metabolism is not fully characterized; as a monoclonal antibody fragment, it is expected to be degraded by proteolysis via general protein catabolism pathways. |
| Excretion | Primarily metabolized in the liver via catabolism to small peptides and amino acids; renal elimination of metabolites is negligible as intact drug is not excreted renally. Biliary/fecal excretion is not a significant route. <1% of dose excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 4.9 days (range 3.5–6.7 days) in patients receiving intravitreal injections every 4 weeks. The long half-life supports sustained intravitreal VEGF suppression with monthly dosing. |
| Protein binding | Unbound in plasma; as a monoclonal antibody fragment, it does not bind significantly to serum proteins. No specific binding proteins identified. |
| Volume of Distribution | Approximately 0.03 L/kg (estimated from systemic exposure following intravitreal injection). The small Vd reflects limited distribution outside the intraocular compartment. |
| Bioavailability | Intravitreal injection: 100% bioavailability (administered directly into the vitreous humor). Not administered by any other route. |
| Onset of Action | Intravitreal injection: Onset of clinical effect (improvement in visual acuity) observed within 1–2 weeks after the first injection, with maximal effect typically achieved after 3–6 months of monthly dosing. |
| Duration of Action | Intravitreal injection: Clinical effect lasts approximately 4 weeks, corresponding to the dosing interval. Sustained efficacy requires continued monthly administration; after cessation, effects gradually wane over 1–2 months. |
10 mg administered via intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; drug is minimally renally excreted. |
| Liver impairment | No dose adjustment required for hepatic impairment; drug is not metabolized by liver. |
| Pediatric use | Not indicated for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; pharmacokinetics similar to younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUSVIMO (SUSVIMO).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Ranibizumab is a large protein (48 kDa) and expected to be present in milk at very low levels if any; systemic absorption after intravitreal injection is negligible. M/P ratio is not available. Caution is advised; consider developmental and health benefits of breastfeeding along with mother's clinical need. |
| Teratogenic Risk | SUSVIMO (ranibizumab intravitreal implant) is not systemically absorbed after intravitreal administration; thus, no direct fetal exposure occurs. No adequate and well-controlled studies in pregnant women. Based on mechanism of action (VEGF inhibition), theoretical risk of impaired fetal angiogenesis if systemic exposure occurs, but systemic levels are negligible. In animal reproduction studies, ranibizumab did not cause fetal harm at intravenous doses up to 260-fold higher than clinical exposure from intravitreal injection. For pregnant women, use only if potential benefit outweighs potential risk. No trimester-specific risks identified due to lack of systemic absorption. |
■ FDA Black Box Warning
Intravitreal injections have been associated with endophthalmitis, retinal detachments, and increased intraocular pressure. Proper aseptic technique is required.
| Serious Effects |
Ocular or periocular infections; active intraocular inflammation; hypersensitivity to ranibizumab or any excipients.
| Precautions | Risk of endophthalmitis and retinal detachment from intravitreal injection; increased intraocular pressure; arterial thromboembolic events; hypersensitivity reactions. |
Loading safety data…
| Fetal Monitoring | Standard monitoring for intraocular administration: ophthalmic examination including visual acuity, intraocular pressure, slit-lamp biomicroscopy, and fundoscopy. No specific maternal or fetal monitoring required for pregnancy or lactation due to negligible systemic exposure. However, consider ultrasound monitoring for fetal growth if used in pregnancy as a precaution. |
| Fertility Effects | No human data on fertility. In animal studies, ranibizumab did not impair male or female fertility at intravenous doses up to 260-fold higher than clinical exposure from intravitreal injection. No effects on reproductive organs in preclinical studies. |